Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

This trial tests a combination of the chemotherapy drug temozolomide plus a cancer vaccine called SurVaxM for people with certain fast-growing neuroendocrine tumors (rare cancers that can arise from the gut, pancreas, or lungs) that are no longer responding to prior treatment. **You may be eligible if...** - You have a confirmed, fast-growing neuroendocrine tumor (ki67 above 20%) from the gut, pancreas, or lungs, or any neuroendocrine carcinoma (excluding small cell lung cancer) - Your tumor tested positive for a protein called survivin - Your cancer has grown or spread over the past 12 months and you have already tried at least one other treatment - You are 18 or older - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You previously received temozolomide and your cancer progressed while on it - You received another clinical trial drug in the last 30 days - You received immunotherapy (checkpoint inhibitors) in the last 3 months - You have an autoimmune disease or are HIV positive - You are on daily steroid doses higher than a small threshold - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.